CA2516931C - Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles - Google Patents

Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles Download PDF

Info

Publication number
CA2516931C
CA2516931C CA2516931A CA2516931A CA2516931C CA 2516931 C CA2516931 C CA 2516931C CA 2516931 A CA2516931 A CA 2516931A CA 2516931 A CA2516931 A CA 2516931A CA 2516931 C CA2516931 C CA 2516931C
Authority
CA
Canada
Prior art keywords
amino
carbonyl
carboxamide
cndot
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2516931A
Other languages
English (en)
Other versions
CA2516931A1 (fr
Inventor
Jacques Dumas
Stephen Boyer
Sharad Verma
Lila Adnane
Yuanwei Chen
Wendy Lee
Barton Phillips
Roger A. Smith
William J. Scott
Jennifer Burke
Jianqing Chen
Zhi Chen
Jianmei Fan
Karl Miranda
Brian Raudenbush
Aniko Redman
Jianxing Shao
Ning Su
Gan Wang
Lin Yi
Qingming Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA2516931A1 publication Critical patent/CA2516931A1/fr
Application granted granted Critical
Publication of CA2516931C publication Critical patent/CA2516931C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne de nouvelle diarylurées, des compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés ou compositions dans le traitement de troubles hyperprolifératifs et de l'angiogenèse, en tant qu'agent unique ou en combinaison avec des thérapies cytotoxiques.
CA2516931A 2003-02-28 2004-03-01 Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles Expired - Fee Related CA2516931C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45034803P 2003-02-28 2003-02-28
US60/450,348 2003-02-28
PCT/US2004/006287 WO2004078748A2 (fr) 2003-02-28 2004-03-01 Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles

Publications (2)

Publication Number Publication Date
CA2516931A1 CA2516931A1 (fr) 2004-09-16
CA2516931C true CA2516931C (fr) 2014-09-09

Family

ID=32962496

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2516931A Expired - Fee Related CA2516931C (fr) 2003-02-28 2004-03-01 Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles

Country Status (5)

Country Link
EP (1) EP1608639A2 (fr)
JP (1) JP5229853B2 (fr)
CA (1) CA2516931C (fr)
MX (1) MXPA05009104A (fr)
WO (1) WO2004078748A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2003068746A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryle-urees en tant qu'inhibiteurs de kinase
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
US7071182B2 (en) * 2003-12-23 2006-07-04 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US20070191444A1 (en) * 2004-02-26 2007-08-16 Hans-Peter Buchstaller Benzimidazolyl derivatives
EP1799661A1 (fr) * 2004-10-08 2007-06-27 AstraZeneca AB Nouveaux amides hydroxymethylbenzothiazoles
EP1868579B1 (fr) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Composition pharmaceutique comprenant une diphénylurée substituée par un oméga-carboxyaryle pour le traitement du cancer
BRPI0502016B8 (pt) * 2005-06-03 2021-05-25 Univ Federal Do Rio De Janeiro Ufrj composto ureídicos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de doenças inflamatórias
AU2007228539B2 (en) 2006-03-23 2013-01-10 Biota Scientific Management Pty Ltd Antibacterial agents
DE102006029795A1 (de) * 2006-06-27 2008-01-03 Schebo Biotech Ag Neue Harnstoff-Derivate und deren Verwendungen
US20100150863A1 (en) 2006-12-20 2010-06-17 Bayer Pharmaceuticals Corporation Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer
EP2185542A2 (fr) 2007-08-15 2010-05-19 Glaxo Group Limited Composés
CN102295600A (zh) * 2011-09-08 2011-12-28 天津大学 5-氨基-8-羟基喹啉的制备方法
WO2013138753A1 (fr) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Promédicaments de riluzole et leur méthode d'utilisation
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
CN104250226B (zh) * 2013-06-27 2019-04-26 常州方楠医药技术有限公司 一种制备瑞格菲尼中间体的方法
WO2017047803A1 (fr) * 2015-09-17 2017-03-23 三栄源エフ・エフ・アイ株式会社 Procédé de production d'une préparation contenant un épaississant polysaccharidique
CA3034332A1 (fr) * 2016-08-17 2018-02-22 Ichan School Of Medicine At Mount Sinai Composes inhibiteurs de kinase, compositions et methodes de traitement du cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001930A (en) 1997-03-13 1999-12-14 Acushnet Company Golf ball forming compositions comprising polyamide blended with sulfonated or phosphonated polymers
NZ503491A (en) * 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
EP1041982B1 (fr) 1997-12-22 2011-10-19 Bayer HealthCare LLC Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees
TR200002618T2 (tr) 1997-12-22 2001-04-20 Bayer Corporation Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi
JP2001526222A (ja) 1997-12-22 2001-12-18 バイエル コーポレイション アリールおよびヘテロアリール置換複素環尿素を使用するｐ３８キナーゼ活性の阻害
UA67763C2 (uk) 1997-12-22 2004-07-15 Байер Фармасьютікалс Корпорейшн Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf
DE1042305T1 (de) 1997-12-22 2001-04-19 Bayer Ag HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
CN1213022C (zh) 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ME00275B (fr) * 1999-01-13 2011-02-10 Bayer Corp DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
MXPA02004594A (es) 1999-11-16 2002-10-23 Boehringer Ingelheim Pharma Derivados de urea como agentes anti-inflamatorios.
DE60229224D1 (de) 2001-04-18 2008-11-20 Euro Celtique Sa Nociceptin-analoga
WO2002085857A2 (fr) * 2001-04-20 2002-10-31 Bayer Corporation Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
JP4927533B2 (ja) * 2003-02-28 2012-05-09 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な置換ピリジン誘導体

Also Published As

Publication number Publication date
WO2004078748A3 (fr) 2004-11-11
MXPA05009104A (es) 2006-05-31
JP5229853B2 (ja) 2013-07-03
JP2006519265A (ja) 2006-08-24
WO2004078748A2 (fr) 2004-09-16
CA2516931A1 (fr) 2004-09-16
EP1608639A2 (fr) 2005-12-28

Similar Documents

Publication Publication Date Title
US8076488B2 (en) Bicyclic urea derivatives useful in the treatment of cancer and other disorders
CA2516931C (fr) Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles
JP4927533B2 (ja) 癌その他の疾患の治療に有用な置換ピリジン誘導体
EP1599466B1 (fr) Derives de 2-oxo-1,3,5-perhydrotriazapine destines au traitement de maladies hyperproliferatives, angiogeniques et inflammatoires
EP1751139B1 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
EP1973897B1 (fr) Dérivés substitués de la pyrimidine utilisables dans le traitement du cancer et d'autres maladies

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220901

MKLA Lapsed

Effective date: 20210301

MKLA Lapsed

Effective date: 20210301